Inflammation and immunosuppression contribute to the pathogenesis of cancer. An increased neutrophil-lymphocyte ratio reflects these processes and is associated with adverse cancer outcomes. Whether anaesthetic technique for breast cancer surgery influences these factors, and potentially cancer recurrence, remains unknown. We conducted a secondary analysis in patients enrolled in an ongoing trial of anaesthetic technique on breast cancer recurrence. The primary hypothesis was that postoperative neutrophil-lymphocyte ratio is lower in patients allocated to receive propofol-paravertebral rather than inhalational agent-opioid anaesthesia for primary breast cancer surgery. Among 397 patients, 116 had differential white cell counts performed pre-operatively and postoperatively. Pre-operative neutrophil-lymphocyte ratio was similar in the propofol-paravertebral 2.3 (95%CI 1.8-2.8) and inhalational agentopioid anaesthesia 2.2 (1.9-3.2) groups, p = 0.72. Postoperative neutrophil-lymphocyte ratio was lower (3.0 (2.4-4.2) vs. 4.0 (2.9-5.4), p = 0.001) in the propofol-paravertebral group. Propofol-paravertebral anaesthesia attenuated the postoperative increase in the neutrophil-lymphocyte ratio.
Introduction
Breast cancer is the most common cancer and leading cause of cancer deaths among women worldwide [1] . Mortality is usually the result of recurrence or metastasis, despite surgical excision of the primary tumour. The peri-operative period may be a decisive window in which competing factors promote or impede metastases developing from residual cancer cells, or for distant micrometastatic disease to escape dormancy [2] .
A retrospective analysis of patients with breast cancer more than a decade ago reported an association between use of regional anaesthesia-analgesia and reduced recurrence [3] .
Since then, the effects of anaesthetic and analgesic techniques on cancer cell signalling and inflammatory response have been studied both in vitro and in retrospective clinical studies with divergent results [4] [5] [6] [7] [8] [9] [10] . Previous retrospective analyses have demonstrated an association between the type of anaesthetic used and survival, with inhalational agent-opioid anaesthesia being associated with a hazard ratio of 1.59 (95%CI 1.30-1.95) for death on univariate analysis when compared with total intravenous anaesthesia (TIVA). This analysis, alongside biological plausibility, has led to further prospective work exploring the effect of anaesthetic technique on survival [11] . Although controversial, mounting retrospective and preclinical data have implicated inhalational anaesthesia and opioid analgesia as independent risk factors for disease recurrence and, conversely, local-regional anaesthesia and propofolbased TIVA as having potential 'chemopreventative' effects [12, 13] .
Increased neutrophil-lymphocyte ratio (NLR) [14] [15] [16] [17] and platelet-lymphocyte ratio (PLR) [18, 19] are recognised inflammatory markers for poor prognosis in solid tumours [20] and reduced time to recurrence in breast cancer [21, 22] . The peri-operative inflammatory process may potentially be influenced by choice of anaesthetic technique, with propofol reported to have anti-inflammatory properties specifically targeting neutrophil activity [23] [24] [25] [26] . The time to return to intended oncologic therapy is an additional metric of peri-operative recovery, since timely resumption of intended postoperative (adjuvant) chemoradiotherapy likely improves outcomes [27, 28] .
We, therefore, tested the hypothesis that NLR would be lower in patients randomly allocated to a propofol-paravertebral anaesthetic technique for primary breast cancer surgery than those given inhalational agent-opioid anaesthesia. Our secondary hypotheses were that postoperative PLR and return to intended oncologic therapy would be lower in patients assigned to propofol-paravertebral anaesthesia.
Methods
The hypothesis that paravertebral analgesia during primary breast cancer surgery reduces breast cancer recurrence is being tested in an ongoing clinical trial (NCT00418457, www.clinicaltrials.gov). Participants are being randomised to receive either propofol anaesthesia and paravertebral analgesia or sevoflurane anaesthesia and opioid analgesia. However, oncologic outcomes will not be available for several years [29] .
The results presented here are based on an unplanned subanalysis of patients who have already been randomly allocated into NCT00418457 at the Mater University Hospital. This subanalysis was conducted with Institutional Review Board approval, with no requirement for consent other than that obtained for the underlying trial. Participants were women who had potentially curative excisional surgery for primary breast cancer. They were randomly allocated to receive either a propofol-paravertebral anaesthetic with propofol-based TIVA and paravertebral block or an inhalational agentopioid anaesthetic with sevoflurane and morphine. The full protocol has been published [29] .
In the propofol-paravertebral group, paravertebral anaesthesia was administered either via a thoracic catheter placed between the T2 and T4 interspaces or via multilevel single injections between the T1 and T5 interspaces [30] . Patients receiving regional anaesthesia were first administered a test dose of lidocaine 1.5% and 1:200,000 adrenaline; this was followed up with a 10-20-ml bolus of bupivacaine 0.5% or ropivacaine 0.5% with adrenaline. Towards the end of surgery, these patients were commenced on an infusion of 6-10 ml. ). This dose was adjustable at the discretion of the attending anaesthetist depending on the extent of surgery, patient co-operation and sufficiency of the block. This is the strategy used in many previous studies of paravertebral analgesia for breast surgery [31] . In the postoperative period, analgesia was provided primarily by the regional block and was supplemented with paracetamol and/or non-steroidal anti-inflammatory (NSAID) drugs as appropriate. Morphine or a similar long-acting opioid was administered if pain relief proved inadequate. At about 24 h postsurgery, patients progressed to paracetamol and/or NSAIDs.
In the inhalational agent-opioid anaesthesia group, general anaesthesia was induced using 1-3 lg.kg À1 fentanyl and 2-4 mg.kg À1 propofol and maintained using sevoflurane. The anaesthetist had discretion to administer sevoflurane and fentanyl in order to sustain heart rate and blood pressure within 20% of pre-operative values. Morphine was administered intravenously at a dose of 0.1 mg.kg À1 towards the end of surgery. Intravenous morphine or a similar long-acting opioid was used postoperatively as needed via nurse-controlled or patient-controlled analgesia. Approximately 24 h postoperatively, patients were transferred to paracetamol and NSAIDs. Nitrous oxide was not used in either group. Inclusion criteria for the underlying study included primary breast cancer without known extension beyond the breast and axillary nodes. Patients must have been scheduled for unilateral or bilateral mastectomy or isolated 'lumpectomy' with axillary node clearance [29] . Exclusion criteria included: previous surgery for breast cancer (except diagnostic biopsies); and any contra-indication to receiving paravertebral anaesthesia or to any of the pharmaceutical agents used. Furthermore, patients were not studied if < 18 years or > 85 years of age or if other systemic disease co-existed which was believed to present a greater than 25% 2-year mortality [29] . Data extracted from patient records included pre-operative and postoperative NLR, PLR and return to intended oncological therapy. Both NLR and PLR were obtained from blood sampled between the first and third postoperative days. Pre-operative NLR > 3.3 is associated with adverse outcomes in patietns with breast tumours [22] , and elevated PLR has also been associated with adverse outcomes [18, 19] .
Return to intended oncologic therapy was defined as the time between surgery and starting or resuming non-surgical oncology therapy (e.g. chemotherapy, radiotherapy or endocrine treatments). These data were obtained from perusing patients' medical records from the date of starting one of these treatments, and calculating the number of days after surgical tumour excision. Delaying oncologic treatments beyond 30-60 days is associated with worse outcomes in breast cancer [32] .
Baseline characteristics, duration of inpatient stay, Charlson comorbidity index [33] and concurrent use of medications were also collected. Oncological data including type, grade and clinical stage of cancer were collected along with the pathological oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) status. Finally, data on major postoperative morbidity such as myocardial infarction, major adverse cardiac event, stroke, pneumonia, venous thrombo-embolism and delirium were also collected.
Existing data indicate that NLR > 3.0 in the postoperative period is associated with increased risk of recurrence in breast cancer. Taking a reduction from a median postoperative value of 3.5 in patients receiving inhalational agent-opioid to 3.0 in the propofolparavertebral group as being, at least theoretically, significant, and noting that the median standard deviation in postoperative NLR data is in the order of 1.1, then 55 patients would be required in each arm of the study, assuming type-1 error = 0.05 and type-2 error = 0.1. Data were recorded on Graph Pad Prism v.6 (GraphPad Prism, GraphPad Software, Inc. La Jolla, CA, USA) [34] and were initially tested for normal distribution using Kolmogorov-Smirnov tests. Normally distributed data were compared using unpaired Student t-tests. Noncontinuous results were compared with the MannWhitney U-test, and within-group data compared with the Wilcoxon rank sum test.
Results
A total of 397 participants were enrolled in NCT 00418457 up to 31 October 2016 at the Mater University Hospital. Among these, 10 participants withdrew from the study, four had incomplete records and 267 lacked both a pre-operative and a postoperative full blood count within three days of their primary surgery. Therefore, the charts of 116 participants were included in this retrospective analysis, with 59 randomly allocated to propofol-paravertebral anaesthesia and 57 to inhalational agent-opioid anaesthesia (Fig. 1) .
Baseline and morphometric characteristics were similar in the two groups and there were no statistically significant differences between them in terms of oncological characteristics, including the fraction of patients with positive oestrogen, progesterone and HER receptors. There were no significant differences in the fraction of patients with positive sentinel lymph nodes or lymphovascular space invasion at the time of surgery ( Table 1 ). The median IQR [range] time after surgery at which postoperative white cell count was obtained was 21 (19-24 [17-46] ) hours. Pre-operative haematology results were similar in each group (Table 2) . Neutrophil-lymphocyte ratio increased significantly in both groups, but more so in patients who received inhalational agent-opioid anaesthesia. Postoperative NLR was 3.0 (2.
The pre-operative to postoperative changes in NLR for each patient are illustrated for the propofol-paravertebral group (Fig. 2a) and the inhalational agent-opioid group (Fig. 2b) . Although the mean changes are shown in Table 3 , these graphs show that, in both groups, some patients' NLR decreased postoperatively rather than increased. There were no significant changes in the PLR in either group Fig. 3 .
Time to return to intended oncologic therapy was 24 weeks in the propofol-paravertebral group vs. 26 weeks in the inhalational agent-opioid anaesthesia group which was not statistically significant (Fig. 4) . However, data on this parameter were difficult to obtain as the patients were part of a geographically diverse group and did not receive follow-up oncological therapy in a single centre. Forty-five out of 59 (76%) patients in the propofol-paravertebral anaesthesia group and 38 out of 57 patients (66%) in the inhalational agent-opioid anaesthesia group had records available regarding time to return to intended oncologic therapy (Table 4) .
Discussion
In this subanalysis of an ongoing randomised trial, we found that propofol-paravertebral anaesthesia for primary breast cancer surgery attenuated the postoperative increase in NLR that was observed in patients who received inhalational agent-opioid anaesthetic. However, the increase, which was statistically significant, was relatively small and probably not prognostically important.
There is a well-identified association between increased systemic inflammation and cancer occurrence [35] . Furthermore, there is an association between cellmediated immunity as an endogenous anticancer response which includes T-helper cells (Th1), cytotoxic CD8 T cells and natural killer (NK) cells [36] . Increased inflammation, as represented by neutrophilia, and reduced cell-mediated immunity, as represented by lymphopenia, both contribute to an increase in NLR. Peri-operatively, due to surgical stress, both inflammation and immune system suppression occur which contribute to a raised NLR [37] . Inhibition of neutrophil apoptosis secondary to surgical stress may also contribute [38] .
A meta-analysis of an association between NLR and disease outcome across a range of tumour types and disease stages indicated that NLR has a clear prognostic value and is associated with worse overall survival when NLR exceeds certain cut-off levels. For example, NLR > 4 was associated with worse overall survival in solid tumours [20] . In studies evaluating NLR for prognosis in breast cancer specifically, non- WCC, white cell count; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio.
operative cut-off values between 3 and 3.3 have been reported [21, 22] . The postoperative NLR in the inhalational agent-opioid group exceeded this value, but was less in patients given propofol. Several studies have examined pre-operative NLR [20] [21] [22] as a prognostic factor. Others have evaluated postoperative NLR [14] [15] [16] , although within approximately a 1-month postoperative period. These do not give an indication of the acute change in NLR in the peri-operative period nor do they study the effect of anaesthetic technique on NLR. Kim et al. studied specific changes in NLR in the peri-operative period in a small group of patients undergoing vaginal hysterectomy [39] . They compared propofol/remifentanil vs. sevoflurane-only anaesthetic regimen and found a transient reduction in NLR at 2 h following surgery in the propofol group but, unlike our findings, this was not statistically significant.
The two distinct anaesthetic techniques examined in our study differ by both the type of anaesthetic used (propofol vs. sevoflurane) as well as the primary perioperative analgesic technique (paravertebral block vs. opioid-based). Therefore, attributing our findings to the relative contributions of the drugs and techniques used to find the NLR differences is not feasible. Opioids have been linked with immunosuppressive effects [40] , whereas regional anaesthesia may attenuate the surgical stress response and inflammation [41] [42] [43] .
There is evidence that propofol may have protective effects against tumour progression and metastases [44, 45] , whereas inhalational anaesthetics have been linked to increased metastatic activity [46, 47] . There is also an association between platelet activity and tumour progression and metastasis [48] , and elevated PLR is associated with reduced survival [18, 19] . We postulated that the expected increase in PLR would be attenuated by propofol-paravertebral anaesthesia which was expected to minimise immunosuppression. However, anaesthetic technique appeared to have little influence on PLR. To the extent that PLR might be a marker for cancer recurrence, our results do not suggest that paravertebral/propofol anaesthesia is protective.
There were also no significant differences in the time to return of intended oncological therapy. There was a limitation in obtaining accurate data on time to return to intended oncological therapy, because data were obtained retrospectively from chart reviews, were not available in a uniform manner and were incomplete in some cases. Patients in the study were part of a geographically diverse group and did not receive follow-up chemotherapy/radiotherapy in a single centre. Furthermore, there was variance in the types of oncological therapy being administered to this cohort of patients.
A limitation of our present study is that we included patients from our centre who had both preand postoperative blood sampling, including a full blood count within 72 h of surgery. However, in both propofol-paravertebral and inhalational agent-opioid anaesthesia groups, more than 95% had their white cell count, and hence NLR, taken on either postoperative Inhalational opioid anaesthetic (IOA) group Figure 3 Change in platelet-lymphocyte ratio (PLR). Pre-operative; PLR Postoperative PLR day 1 or 2. There were also a small number (< 5%) in each group with samples from up to 72 h postoperatively included. Only about half of our study patients had blood sampled for cell counting postoperatively; it is possible that results would differ had all patients been included. However, it is plausible that postoperative blood sampling was undertaken for clinical reasons, which might have had a greater influence on NLR than anaesthetic technique. A previous study evaluated postoperative NLR at 3-4 months after surgery [17] . It is possible that propofol and sevoflurane have direct effects on platelets, neutrophils or lymphocytes that are independent of any generalised immune activation or inhibition. Surgical stress, which may or may not influence cancer recurrence, certainly releases catecholamines which, in turn, increase circulating neutrophils. Consistent with this theory, the NLR increased in nearly all patients but such changes may not convey prognostic information about cancer recurrence.
In conclusion, in this retrospective analysis of an ongoing RCT, propofol-paravertebral anaesthesia attenuated the postoperative increase in the NLR, but the effect was small. Furthermore, neither the PLR nor return to intended oncologic treatment were affected.
